3MC Syndrome — Comprehensive Disease Characterization Report

Prepared for a disease knowledge base entry. Evidence type is human clinical unless otherwise noted (model organism / in vitro / computational). Primary literature cited by PMID.

Summary (Answer to the Research Question)

3MC syndrome is a rare, autosomal-recessive congenital malformation syndrome that unifies four historically separate disorders — Malpuech, Michels, Mingarelli and Carnevale syndromes ("3MC"). It is caused by biallelic loss-of-function variants in one of three genes of the lectin pathway of complement: MASP1 (encoding MASP-1/MASP-3), COLEC11 (encoding collectin-11/CL-K1), and COLEC10 (encoding collectin-10/CL-L1). The shared mechanism is loss of a collectin/MASP-3 chemoattractant guidance cue required for neural crest cell migration, producing a distinctive facial gestalt (hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows) together with cleft lip/palate, postnatal growth deficiency, developmental delay, hearing loss, a characteristic caudal appendage, skeletal (craniosynostosis, radioulnar synostosis) and genitourinary anomalies (PMIDs 21258343, 28301481).

1. Disease Information

• Overview: A rare autosomal-recessive multiple-congenital-anomaly / dysmorphism syndrome affecting craniofacial, skeletal, genitourinary, ophthalmic and (variably) cardiac development. The name "3MC" was proposed as a unifying term for the overlapping Carnevale, Mingarelli, Malpuech and Michels syndromes (PMID 21258343).
• Key identifiers (suggested):
• MONDO: MONDO:0018721 ("3MC syndrome") — with subtypes 3MC syndrome type 1/2/3.
• OMIM (phenotype): 3MC syndrome 1 (#257920, MASP1/COLEC11 — historically Malpuech/Carnevale), 3MC syndrome 2 (#265050, COLEC11), 3MC syndrome 3 (#248340, COLEC10 — historically Michels). (PMIDs 36503917, 34636477)
• OMIM (gene): MASP1 600521; COLEC11 612502; COLEC10 *607620.
• Orphanet: ORPHA:293843 (3MC syndrome); legacy entries Malpuech syndrome (ORPHA:1993), Michels syndrome (ORPHA:1394), Carnevale/Mingarelli.
• ICD-10: Q87.0 (congenital malformation syndromes predominantly affecting facial appearance). ICD-11: LD2F.0Y (other specified syndromes with facial features as a major feature).
• MeSH: No dedicated descriptor; indexed under "Abnormalities, Multiple" / supplementary concept "3MC syndrome."
• Synonyms / alternative names: Malpuech–Michels–Mingarelli–Carnevale syndrome; Malpuech facial clefting syndrome; Michels syndrome; Carnevale syndrome; Mingarelli syndrome; Malpuech syndrome; OSA syndrome; craniofacial-ulnar-renal syndrome; blepharophimosis-ptosis-cleft-lip syndrome (descriptive).
• Data derivation: Information here is derived from aggregated disease-level resources (OMIM/Orphanet) and individual patient case reports / small cohorts (fewer than ~100 molecularly confirmed patients worldwide). There is no large EHR-based dataset for this ultra-rare disorder.

2. Etiology

• Primary cause — genetic: Biallelic (homozygous or compound heterozygous) pathogenic variants in MASP1, COLEC11, or COLEC10 — all encoding components of the lectin complement pathway (PMID 21258343: "identified two mutated genes, COLEC11 and MASP1, both of which encode proteins in the lectin complement pathway"; PMID 28301481 for COLEC10). There is evidence of further genetic heterogeneity: some clinically typical patients from consanguineous families have no MASP1/COLEC11/COLEC10 variant (PMID 26789649).
• Genetic risk factors:
• Causal variants in the three genes (Section 4).
• Consanguinity — a major risk factor; most reported families are consanguineous with homozygous variants.
• Founder alleles — e.g., COLEC10 c.311G>T (p.Gly104Val) in Ashkenazi Jews (carrier frequency ~1/99; PMID 35943032); COLEC10 c.807_810delCTGT in Apulia, Italy (PMID 34740859).
• Modifier genes: Model-organism data suggest other complement components (MASP-2, factor B, C3) may modify skeletal severity (PMID 41774788, model organism).
• Environmental risk factors: None established. 3MC is a monogenic Mendelian disorder; no toxin, infectious, lifestyle, occupational, age or sex exposure is a known cause. (Not applicable.)
• Protective factors: No genetic or environmental protective factors described for the developmental syndrome. (Free L-fucose is protective against CL-11-mediated renal ischemia-reperfusion injury in mice — PMID 31914693 — but this concerns adult acquired injury, not the developmental syndrome.)
• Gene–environment interactions: None documented for 3MC syndrome. (Not applicable.)

3. Phenotypes

Frequencies drawn largely from a 7-patient cohort (PMID 41703727) and case series (PMIDs 36503917, 26789649). Onset is congenital/prenatal for structural features; course is generally stable/non-progressive (malformative) with lifelong sequelae.

• Age of onset: Congenital/prenatal (structural malformations detectable prenatally — bilateral cleft lip/palate + sacral protuberance + renal anomaly; PMID 32441374). Growth deficiency is postnatal.
• Severity: Variable (mild to severe), even within the same gene and family (PMID 29407414 describes an adult with the facial gestalt but without cleft lip/palate, intellectual disability, or short stature).
• Progression: Non-progressive/stable malformative disorder; sequelae are lifelong.
• Quality-of-life impact: Cleft repair, hearing loss, developmental delay, short stature and limb/skeletal anomalies affect feeding, speech, hearing, mobility and learning; no formal EQ-5D/SF-36 studies exist for this ultra-rare disease (not available).

4. Genetic / Molecular Information

• Causal genes (HGNC / locus / OMIM gene / product):
• MASP1 — HGNC:6901; 3q27.3; 600521; encodes MASP-1 and MASP-3 (alternative splicing). 3MC-causing variants are truncating, or missense within exon 12* encoding the MASP-3-specific C-terminal serine protease domain (PMID 29407414).
• COLEC11 — HGNC:17213; 2p25.3; 612502; encodes collectin-11 (CL-K1 / CL-11 / collectin kidney-1)*.
• COLEC10 — HGNC:2311; 8q24.12; 607620; encodes collectin-10 (CL-L1 / collectin liver-1)*.
• Representative pathogenic variants (all germline, biallelic):
• COLEC11 p.Gly204Ser — associated with undetectable serum protein (PMID 25912189, in vitro).
• COLEC10 p.Arg9Ter (c.25C>T), p.Gly77Glufs*66 (c.226delA), p.Cys176Trp (c.528C>G) — impair CL-L1 expression/secretion (PMID 28301481, in vitro).
• COLEC10 c.311G>T; p.Gly104Val — Ashkenazi Jewish founder variant (PMID 35943032).
• COLEC10 c.807_810delCTGT; p.Cys270Serfs*33 (loss of natural stop, +24 aa) — Apulian founder (PMID 34740859).
• COLEC10 c.128_129delCA; p.Thr43AsnfsTer9 — Iranian, first homozygous frameshift (PMID 34636477).
• MASP1 c.310C>T; p.Gln104Ter — nonsense (PMID 33765348).
• MASP1 homozygous ~2 kb intragenic deletion partially affecting exon 12; also exon-level deletions (PMIDs 29407414, 41703727) — may be missed by standard exome pipelines.
• Variant classification & type: Pathogenic/likely pathogenic per ACMG/AMP; predominantly loss-of-function — nonsense, frameshift, splice, intragenic/exon-level deletions, and secretion-impairing missense. Functional consequence = loss of function (protein deficiency or non-secretion). No gain-of-function or dominant-negative mechanism reported.
• Allele frequency: Causal alleles are rare/absent in gnomAD except population-specific founders (Ashkenazi COLEC10 carrier freq ≈1.01%, PMID 35943032).
• Somatic vs germline: Exclusively germline, biallelic (autosomal recessive). No somatic/COSMIC relevance.
• Modifier genes: Complement components MASP-2, factor B, C3 modulate skeletal phenotype in mice (PMID 41774788, model organism).
• Epigenetics: No disease-specific methylation/histone signature reported (not available).
• Chromosomal abnormalities: None characteristic; the disorder is caused by single-gene point/indel/small-deletion variants (some detectable only by careful CNV analysis of WES/WGS; PMID 29407414).

Suggested gene/GO annotations: MASP1/COLEC11/COLEC10; GO:0001867 (complement activation, lectin pathway), GO:0030246 (carbohydrate binding), GO:0005509 (calcium ion binding).

5. Environmental Information

• Environmental factors: None known. (Not applicable — Mendelian disorder.)
• Lifestyle factors: None known (not applicable).
• Infectious agents: None (not applicable). Note the biological irony that the causative genes are innate-immune anti-microbial pattern-recognition molecules, but the syndrome itself is developmental, not infectious.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream): Biallelic LOF variant in MASP1/COLEC11/COLEC10 → deficient or mis-secreted collectin (CL-K1 or CL-L1) or non-functional MASP-3 → loss of the CL-K1·MASP-3 chemoattractant guidance cue for cranial neural crest cells (cNCC) → aberrant NCC migration/differentiation → malformation of NCC-derived and midline structures (craniofacial skeleton, palate, heart outflow, genitourinary tract, vertebral/coccygeal elements) → clinical phenotype (PMID 21258343).

• Molecular pathways: Lectin pathway of complement (and its link to the alternative pathway). CL-K1/CL-L1 form Ca²⁺-dependent heteromeric collectin complexes that associate with MASP-1/2/3 (PMID 27782323). MASP-3 is the exclusive pro-factor D activator in resting blood, linking the lectin and alternative pathways (PMID 27535802: "activated MASP-3 is the exclusive pro-FD activator in resting blood, which demonstrates a fundamental link between the lectin and alternative pathways.").
• Cellular processes: Neural crest cell migration (GO:0001755) — CL-K1 acts as a directional guidance cue (PMID 21258343). Also osteoclast differentiation (GO:0030316) — CL-11 regulates osteoclastogenesis complement-dependently (PMID 41774788, model organism/in vitro).
• Protein dysfunction: LOF via impaired secretion and loss of Ca²⁺ binding in the carbohydrate-recognition domain (CRD). Disease mutations do not necessarily block folding/oligomerization in vitro, but abolish Ca²⁺ binding and secretion, producing serum protein deficiency (PMID 25912189, in vitro).
• Metabolic/biochemical: CL-K1 recognizes high-mannose oligosaccharides and L-fucose on stressed/altered self-surfaces (PMIDs 25912189, 31914693). Enzymatically, MASP-3 has low amidolytic activity relative to other C1r/C1s/MASP proteases (PMID 23861840, in vitro/structural).
• Immune involvement: The causative molecules are innate-immune complement effectors; however, 3MC patients are not primarily immunodeficient — the phenotype reflects the developmental (non-immune) moonlighting role of these proteins ("a broader functionality of the complement system than previously anticipated," PMID 27782323).
• Tissue-damage mechanism (adult context): In acquired renal ischemia-reperfusion injury, CL-11 binds a fucosylated damage ligand on tubular epithelium and triggers complement/C5b-9 injury — mechanistically informative but distinct from the developmental syndrome (PMIDs 28663231, 31914693, model organism).
• Molecular profiling / omics / single-cell / CRISPR screens: No disease-specific transcriptomic, proteomic, metabolomic or functional-genomics screens published for 3MC (not available); mechanistic evidence is from targeted zebrafish morphants, mouse expression/knockout, and in vitro biochemistry.

Suggested ontology terms: GO:0001755 (neural crest cell migration), GO:0001867 (lectin-pathway complement activation), GO:0030316 (osteoclast differentiation), GO:0045087 (innate immune response); CL:0000333 (migratory neural crest cell / cranial NCC), CL:0000138 (chondrocyte), CL:0000092 (osteoclast); CHEBI:2181 (L-fucose), CHEBI:29108 (calcium(2+)), CHEBI:37671 (high-mannose oligosaccharide/mannose).

7. Anatomical Structures Affected

• Organ / system level:
• Craniofacial skeleton & face (UBERON:0001456 face; UBERON:0001716 secondary palate) — cleft lip/palate, hypertelorism, dysmorphism.
• Skull sutures (UBERON:0000905) — craniosynostosis.
• Eyes / periocular (UBERON:0000970) — blepharophimosis, ptosis, anterior-segment dysgenesis (UBERON:0000481 anterior chamber).
• Skeleton / limbs — radioulnar synostosis (radius UBERON:0001423 / ulna UBERON:0001424); vertebral column/coccyx (UBERON:0009832) — caudal appendage.
• Kidney & urinary tract (UBERON:0002113) — horseshoe/pelvic kidney, vesicoureteral reflux.
• Genitalia (UBERON:0000990) — genital anomalies.
• Heart (UBERON:0000948) — congenital heart disease (e.g., PDA).
• Ear / auditory system (UBERON:0001690) — hearing loss.
• CNS — developmental delay/cognitive impairment (functional).
• Tissue / cell level: Connective/skeletal tissue (cartilage, bone) and epithelial (palatal) tissue; the key targeted cell population is the cranial neural crest cell (CL:0000333) and its derivatives (chondrocytes, cranial mesenchyme); osteoclasts implicated in skeletal maintenance (PMID 41774788).
• Subcellular level: Secreted proteins traffic through the endoplasmic reticulum / secretory pathway (GO:0005783 ER; GO:0005576 extracellular region); LOF mutations cause ER retention / secretion failure (PMID 25912189).
• Localization / lateralization: Malformations are typically bilateral/midline (bilateral cleft lip/palate, hypertelorism, radioulnar synostosis often bilateral), consistent with a midline/symmetric developmental patterning defect.

8. Temporal Development

• Onset: Congenital — structural anomalies arise during embryogenesis and are detectable prenatally (first prenatal diagnosis: bilateral cleft lip/palate + sacral abnormality + pelvic kidney + brachycephaly; PMID 32441374). Growth deficiency is postnatal.
• Onset pattern: Non-acute; features are present from birth (insidious/static developmental).
• Progression: Non-progressive malformative syndrome; stable course. Skeletal contractures or scoliosis may require intervention over time (e.g., knee flexion contracture managed with a Taylor Spatial Frame — PMID 34589314).
• Disease course / duration: Chronic, lifelong; individuals can survive to adulthood (PMID 29407414 describes a 21-year follow-up in an adult).
• Remission / critical periods: No remission (structural). The critical window is embryonic craniofacial neural-crest migration; interventions are corrective/supportive postnatally rather than preventive of the malformation.

9. Inheritance and Population

• Epidemiology: Ultra-rare; <50 molecularly confirmed COLEC11/MASP1 patients reported as of 2020 (PMID 32441374), with additional COLEC10 cases since. Formal prevalence/incidence per 100,000 is not established (not available).
• Inheritance: Autosomal recessive (all three genes) (PMIDs 21258343, 28301481).
• Penetrance / expressivity: Presumed high penetrance for a recognizable phenotype in biallelic carriers, but highly variable expressivity (mild adult cases lacking cleft/ID/short stature — PMID 29407414).
• Genetic anticipation: Not applicable (no repeat expansion).
• Germline mosaicism: Not reported.
• Founder effects / consanguinity: Strong role of consanguinity; documented founders — Ashkenazi Jewish COLEC10 c.311G>T (carrier frequency 1 in 99, PMID 35943032) and Apulian (Italian) COLEC10 c.807_810delCTGT (PMID 34740859).
• Carrier frequency: ≈1.01% in Ashkenazi Jews for the COLEC10 founder allele; otherwise very rare (PMID 35943032).
• Population demographics: Cases reported worldwide (Turkey/Kurdish, Iran, Italy, Mexico, Ashkenazi Jewish, and others), often from consanguineous or founder populations. Sex ratio: roughly equal (autosomal; cohort of 7 had 5 F / 2 M — small-sample skew, PMID 41703727). Age distribution: predominantly diagnosed in infancy/childhood.

10. Diagnostics

• Clinical recognition: Diagnosis is suspected on the facial gestalt (hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows) plus cleft lip/palate and — a relatively specific clue — a caudal appendage (PMIDs 34899147, 26789649).
• Genetic testing (confirmatory, gold standard):
• Whole-exome (WES) / whole-genome (WGS) sequencing or a 3MC/multiple-congenital-anomaly gene panel covering MASP1, COLEC11, COLEC10. Important caveat: some clinical exome panels omit COLEC10, causing missed diagnoses — targeted Sanger of COLEC10 may be needed (PMID 34740859).
• CNV / deletion analysis: exon-level and intragenic deletions occur (MASP1) and can be missed by routine pipelines — require careful visual/CNV analysis of WES/WGS (PMIDs 29407414, 41703727).
• Single-gene / Sanger for founder alleles (e.g., Ashkenazi COLEC10 c.311G>T).
• Karyotype/FISH/mtDNA/repeat-expansion testing: not indicated (normal/uninformative).
• Biomarkers / functional assays: Serum/plasma CL-K1 or CL-L1 levels may be reduced/undetectable with secretion-impairing variants (PMID 25912189), but levels can be normal despite pathogenic variants (PMID 34740859) — so protein level is supportive, not definitive.
• Imaging: Prenatal ultrasound (facial clefts + sacral/spinal defect + renal anomaly; PMID 32441374); postnatal skeletal survey/radiographs (radioulnar synostosis, craniosynostosis, coccygeal appendage); renal ultrasound; echocardiography; audiology; ophthalmologic exam (anterior-segment).
• Clinical criteria / differential diagnosis: No formal consensus criteria. Differential includes other blepharophimosis–ptosis syndromes (e.g., BPES), oral-facial-clefting syndromes, Fraser syndrome, and other craniofacial-limb-renal syndromes; the caudal appendage + radioulnar synostosis + facial gestalt combination and molecular confirmation distinguish 3MC (PMID 35943032 notes 3MC should be in the differential for short stature + radioulnar synostosis + cleft lip/palate).
• Screening: Carrier / cascade screening in founder populations (Ashkenazi Jewish COLEC10) and consanguineous families; prenatal molecular testing feasible once a family variant is known (PMID 32441374). No newborn-screening program exists.

11. Outcome / Prognosis

• Survival / mortality: No formal survival statistics; the disorder is generally compatible with survival to adulthood (PMID 29407414, 21-year follow-up). Severe multi-organ involvement (cardiac, renal) can affect prognosis in individual cases.
• Morbidity / function: Chronic disability from cognitive impairment, hearing loss, short stature, cleft-related speech/feeding issues, and skeletal/limb constraints (radioulnar synostosis, contractures). Variable — some individuals have mild, near-normal cognition (PMID 29407414).
• Quality-of-life measures: No disease-specific QoL data (not available).
• Complications: Cleft-related feeding/speech difficulties and otitis/hearing loss; renal anomalies may predispose to urinary complications; skeletal contractures/scoliosis; psychiatric comorbidity reported (ADHD/ODD/depression; PMID 37463393).
• Recovery / prognostic factors: Malformations are static; outcomes improve with corrective surgery, hearing rehabilitation, and developmental support. Prognosis is modulated by severity of cardiac/renal/CNS involvement. No validated prognostic biomarkers.

12. Treatment

No disease-modifying or gene-specific therapy exists. Management is multidisciplinary, symptomatic, and supportive.

• Pharmacotherapy: None specific to 3MC. Symptomatic (e.g., stimulants/SSRIs for comorbid ADHD/depression as clinically indicated; PMID 37463393). No pharmacogenomic considerations established. (NCIT: Supportive Care; Symptomatic Treatment.)
• Advanced therapeutics (gene/cell/RNA/targeted/immuno): None approved or in trials for 3MC (not applicable). The lectin-pathway/CL-11 axis is a therapeutic target in acquired renal IRI (L-fucose decoy strategy, PMID 32472330, model organism) — not for the developmental syndrome.
• Surgical / interventional: Cleft lip and palate repair (NCIT: Cleft Lip Repair / Cleft Palate Repair); craniofacial/craniosynostosis surgery; ptosis/blepharophimosis correction; orthopedic correction of limb contractures/synostosis (e.g., Taylor Spatial Frame for knee flexion contracture, PMID 34589314); urologic/genital corrective surgery as needed.
• Supportive / rehabilitative: Hearing aids/audiologic management; speech therapy; physical/occupational therapy; growth and nutritional monitoring; developmental/educational support; ophthalmologic care.
• Treatment strategy: Individualized, coordinated by clinical genetics + craniofacial/plastic surgery, ENT/audiology, orthopedics, urology/nephrology, cardiology, ophthalmology, and developmental pediatrics. Genetic counseling is integral.
• Experimental treatments / trials: None registered specifically for 3MC (not available).

Suggested NCIT terms: Supportive Care; Surgical Procedure; Cleft Lip Repair; Cleft Palate Repair; Physical Therapy; Genetic Counseling; Hearing Aid.

13. Prevention

• Primary prevention: Not preventable once conceived (congenital genetic disorder). Preconception risk reduction via genetic counseling for consanguineous couples and known-carrier families.
• Secondary prevention / early detection: Prenatal molecular diagnosis and prenatal ultrasound (facial clefts + sacral/renal anomalies) enable early identification and reproductive planning (PMID 32441374). Preimplantation genetic testing (PGT-M) is an option when the familial variant is known.
• Genetic screening: Carrier and cascade screening — high-yield in the Ashkenazi Jewish population for COLEC10 c.311G>T (carrier ~1/99) and in consanguineous/founder populations (PMID 35943032).
• Counseling: Autosomal-recessive recurrence risk 25% per pregnancy for carrier couples; molecular confirmation "allows for alternate reproductive options" (PMID 32441374).
• Tertiary prevention: Early cleft repair, hearing rehabilitation, developmental therapy, and orthopedic/urologic surveillance to limit complications.
• Immunization / public-health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy of gene orthologs: MASP1, COLEC11, COLEC10 are conserved in vertebrates — Mus musculus (NCBI Taxon 10090), Danio rerio (7955), Homo sapiens (9606).
• Naturally occurring animal disease: No naturally occurring 3MC-equivalent Mendelian disease is catalogued in companion animals/livestock (OMIA — not available). Phenotypes are known only from engineered/experimental models.
• Comparative biology / conservation: The lectin complement pathway and its developmental role are evolutionarily conserved; zebrafish colec11/masp1 knockdown reproduces craniofacial and pigmentary defects (PMID 21258343), demonstrating conserved mechanism.
• Transmission / zoonosis: Not applicable (genetic, non-transmissible).

15. Model Organisms

• Zebrafish (Danio rerio, ZFIN): Morpholino knockdown (morphants) of colec11 or masp1 produce pigmentary defects and severe craniofacial abnormalities — the key model recapitulating the human craniofacial phenotype and demonstrating the neural-crest guidance mechanism (PMID 21258343, model organism). Recapitulation: strong for craniofacial/neural-crest features.
• Mouse (Mus musculus, MGI):
• Expression studies: CL-K1 is highly expressed in embryonic craniofacial cartilage, heart, bronchi, kidney, and vertebral bodies (PMID 21258343); COLEC10/CL-L1 is expressed in the base membrane of the developing palate (PMID 28301481) — spatially concordant with affected human structures.
• Knockouts: CL-11 (Colec11) knockout alone does not reproduce skeletal abnormalities; combined CL-11 + MASP-2 / factor B / C3 deficiency causes vertebral bone loss and spinal curvature via impaired osteoclastogenesis (PMID 41774788, model organism) — a limitation (single-gene mouse KO under-recapitulates the human skeletal phenotype) and a clue that complement modifiers matter.
• In vitro / cellular models: Mammalian expression systems demonstrating that disease mutations block CL-K1/CL-L1 secretion and Ca²⁺ binding (PMIDs 25912189, 28301481); human iPSC-derived osteoclasts showing CL-11 dependence (PMID 41774788); recombinant MASP-3 serine-protease domain structural/enzymatic studies (PMID 23861840).
• Model limitations: Mouse single-gene KOs incompletely reproduce the full malformation spectrum (skeletal features require compound complement deficiency); morpholino zebrafish models capture craniofacial/pigment phenotypes but are transient knockdowns.
• Resources: ZFIN (zebrafish), MGI/IMPC (mouse), Cellosaurus (iPSC lines).

Evidence Source Summary

Limitations and Future Directions

• Ultra-rarity: <~100 molecularly confirmed patients; frequencies are from small cohorts and case reports, limiting precision of penetrance/expressivity and genotype–phenotype correlation.
• Genetic heterogeneity: Some clinically typical, consanguineous patients lack variants in the three known genes (PMID 26789649) — additional lectin-pathway genes likely remain to be discovered.
• No omics datasets: No published transcriptomic/proteomic/metabolomic/single-cell profiling of patient tissues; mechanism rests on targeted models and biochemistry.
• Future directions: Deeper phenotyping registries; CNV-aware sequencing (to capture exon-level deletions); functional CL-K1/CL-L1 assays as adjunct diagnostics; delineating the neural-crest guidance mechanism at single-cell resolution; exploring complement modifiers of skeletal severity.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0018721 (1 mention) - the report calls it "3MC syndrome"; MONDO calls it obsolete rare combined vascular malformation
• HP:0000316 (1 mention) - the report calls it "physical/craniofacial sign"; HP calls it Hypertelorism
• HP:0000581 (1 mention) - the report calls it "physical sign"; HP calls it Blepharophimosis
• HP:0000508 (1 mention) - the report calls it "physical sign"; HP calls it Ptosis
• HP:0002553 (1 mention) - the report calls it "physical sign"; HP calls it Highly arched eyebrow
• HP:0000537 (1 mention) - the report calls it "physical sign"; HP calls it Epicanthus inversus
• HP:0000494 (1 mention) - the report calls it "physical sign"; HP calls it Downslanted palpebral fissures
• HP:0000365 (1 mention) - the report calls it "lab/functional sign"; HP calls it Hearing impairment
• HP:0100541 (1 mention) - the report calls it "tail-like"; HP calls it Femoral hernia
• HP:0001363 (1 mention) - the report calls it "physical sign"; HP calls it Craniosynostosis
• HP:0003042 (1 mention) - the report calls it "physical sign"; HP calls it Elbow dislocation
• HP:0007700 (1 mention) - the report calls it "ophthalmic sign"; HP calls it Ocular anterior segment dysgenesis
• HP:0001537 (1 mention) - the report calls it "physical sign"; HP calls it Umbilical hernia
• HP:0004209 (1 mention) - the report calls it "physical sign"; HP calls it Clinodactyly of the 5th finger
• HP:0011003 (1 mention) - the report calls it "ophthalmic sign"; HP calls it High myopia
• CHEBI:37671 (1 mention) - the report calls it "high-mannose oligosaccharide/mannose"; CHEBI calls it (1->3)-beta-D-glucan
• UBERON:0000970 (1 mention) - the report calls it "Eyes / periocular"; UBERON calls it eye
• UBERON:0002113 (1 mention) - the report calls it "Kidney & urinary tract"; UBERON calls it kidney

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• UBERON:0000905 (1 mention), reported as "Skull sutures" - UBERON does not contain this term
• UBERON:0009832 (1 mention), reported as "coccyx" - UBERON does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• MONDO:0018721 (obsolete rare combined vascular malformation) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0001755 (2 mentions) - the report calls it "Neural crest cell migration", "Cellular processes: Neural crest cell migration", "neural crest cell migration"; GO calls it neural crest cell migration
• CHEBI:2181 (1 mention) - the report calls it "L-fucose"; CHEBI calls it L-fucopyranose, and lists "(-)-L-Fucose" among its other names
• UBERON:0000990 (1 mention) - the report calls it "Genitalia"; UBERON calls it reproductive system, and lists "genitalia" among its other names
• UBERON:0001690 (1 mention) - the report calls it "Ear / auditory system"; UBERON calls it ear, and lists "auditory apparatus" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• GO:0001867 - called "complement activation, lectin pathway", "lectin-pathway complement activation"
• GO:0001755 - called "Neural crest cell migration", "Cellular processes: Neural crest cell migration", "neural crest cell migration"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.